Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-010: Pembrolizumab/Vibostolimab vs Pembrolizumab in High-risk Melanoma
NCT05665595Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Countries
- 26
01
Overview
A Phase 3 trial of vibostolimab in melanoma, sponsored by Merck & Co.. Started Jan 2023; status: terminated.
02
Drugs
vibostolimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05665595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665595.